Thelper is a biotechnology company based in Oslo, Norway, focusing on the development of innovative treatments for incurable cancers. Leveraging the potential of targeted immunotherapy, Thelper aims to address the limitations of current cancer therapies in treating solid tumors. The company's research revolves around the manipulation of T helper cells and the TIM-3 molecule to regulate immune responses and induce peripheral tolerance. By exploring the molecular mechanisms of T-helper type 2 (Th2) inflammation and its mediators such as IL-4, IL-5, and IL-13, Thelper is at the forefront of creating impactful innovations in cancer therapy. Situated within the Oslo Cancer Cluster, Thelper collaborates with a network of oncology research and industry experts to advance its mission of transforming cancer treatment.